February 27, 2017
CTI BioPharma appoints hematology specialist as CEO
CTI BioPharma has appointed Adam Craig, M.D., Ph.D., as President and Chief Executive Officer (CEO) and member of the Board of Directors
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
February 27, 2017
Global Market Insights says clinical trial management system market worth $2 billion by 2024
Growing prevalence of chronic diseases, surge in clinical trials outsourcing, rising R&D cost and favorable government initiatives will drive global clinical trial management system market size, according to a report by Global Market Insights.
February 24, 2017
Novartis makes first step in making Tafinlar + Mekinist available for certain NSCLC patients
Novartis could get first targeted treatment for patients with BRAF non-small cell lung cancer if European Medicines Agency (EMA) approves Tafinlar+Mikinist combination.
February 24, 2017
Oncology focused drugmaker Xynomic Pharmaceuticals secures Abexinostat global rights
Oncology drug research and development company Xynomic Pharmaceuticals has acquired exclusive worldwide rights to develop a novel HDAC inhibitor targeting hematological and solid tumors, Abexinostat.
February 24, 2017
Galapagos starts Phase 1 study for cystic fibrosis drug, reports net profit of €54M for 2016
Galapagos has started dosing the first healthy volunteer with a combination of novel corrector GLPG2222 and novel potentiator GLPG2451 for cystic fibrosis in a Phase 1 study.
February 24, 2017
OncoGenex has enough money for next year as it waits a mid-year merger with Achieve Life Sciences
Vancouver-based drugmaker OncoGenex didn’t make any revenues in the fourth quarter 2016, and it finished the year with a net loss for the fourth quarter and year ended December 31, 2016 of $5.8 million and $20.1 million, respectively.
February 24, 2017
Oxford BioMedica reports positive results for advanced colorectal cancer drug
Oxford BioMedica, a gene and cell therapy group, has presented results from a Phase I/II clinical trial of MVA-5T4 immunotherapy (TroVax) and low dose cyclophosphamide (CPM) in patients with advanced colorectal cancer (TaCTiCC).
February 23, 2017
Valeant under magnifying glass of research reports coverage on healthcare stocks
Canada-based drugmaker Valeant Pharmaceuticals was put in focus for an online stock market analyist among several other healthcare companies. Valeant and EyeGate inked a deal for worldwide commercial and manufacturing rights to a product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients.
February 23, 2017
China updates key drug list in boost for Big Pharma
China has updated list of medicines covered by basic medical insurance schemes, a long-awaited fillip for drugmakers in the world’s second-largest drug market where many new drugs have been kept out of patients’ reach because of high costs.
February 23, 2017
Abivax discovers molecules active against dengue fever
Abivax, a biotechnology company targeting the immune system to eliminate viral diseases, has recently discovered several molecules that are active against the virus in vitro, some of which could be developed as therapeutic drug-candidates against dengue fever.